eli lilly oral tirzepatide launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, (Zepbound). The device gives patients an additional, potentially more convenient option for taking the drug: They can FDA Approves Lilly's Zepbound for

*This statement has not been evaluated by the FDA

The no-subscription model is particularly valuable for patients who want to pause treatment or adjust their timeline without penalty

Speak to your doctor about testing your testosterone level during your next checkup

Navarro Negredo, P., Yeo, R

We sometimes had clients with severe bowel impactions, and I wonder if carnitine deficiency was at the root of this

Weight loss from Semaglutide GLP-1 may not be permanent without ongoing lifestyle modifications and support, but with appropriate strategies, it is possible to sustain weight loss after discontinuing Semaglutide GLP-1 treatment